Farnesyltransferase inhibitors: Novel anticancer mechanisms and new therapeutic applications

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 5, 2000, Pages 585-596

  Gibbs, R A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Bisphosphonate; Farnesyl; Geranylgeranyl; Osteoporosis; Restenosis; Rho protein; Statin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 [2 [4 (3,10 DIBROMO 8 CHLORO 6,11 DIHYDRO 5H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YL) 1 PIPERIDINYL] 2 OXOETHYL] 1 PIPERIDINECARBOXAMIDE; A 176120; ABT 839; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BMS 214662; CYTOTOXIC AGENT; FARNESYL TRANS TRANSFERASE; FLAVOPIRIDOL; GGTI 2166; GGTI 298; L 282964; L 689230; L 778123; NITROGEN DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; R 115777; RHO FACTOR; RPR 130401; RPR 13041; TAXOL; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG POTENCY; DRUG SCREENING; HUMAN; NAUSEA; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRENYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; RESTENOSIS; REVIEW;

EID: 0033778340     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Enzymology and biology of CAAX protein prenylation
2. Recent advances in the study of prenylated proteins
3. Farnesyl protein transferase: A review of structural studies
4. Recent studies of the mechanism of protein prenylation
5. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
6. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
7. Ras farnesyltransferase: A new therapeutic target
8. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
9. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
10. Multivariate date analysis using D-optimal designs, partial least squares, and response surface modeling: A directional approach for the analysis of farnesyltransferase inhibitors
11. Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue
12. Novel farnesol and geranylgeraniol analogues: A potential new class of anticancer agents directed against protein prenylation
13. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner
14. C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice
15. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
16. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
17. Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferase
18. Discovery of a series of cyclohexylethylamine-containing protein farnesyl transferase inhibitors exhibiting potent cellular activity
19. A peptidomimetic inhibitor of Ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility
20. Synthesis of A-228839.25, farnesyl transferase inhibitor
21. A phase II study of farnesyl transferase inhibitor R115777 in patients with advanced breast cancer
22. A phase I and pharmacologic study of the farnesyl protein transferase (FPT) inhibitor SCH 66336 in patients with locally advanced or metastatic cancer
23. Phase I and pharmacokinetic study of SCH 66336, a novel FPTI, using a 2-week on, 2-week off schedule
24. A phase I and pharmacologic study of continuous daily oral SCH 66336, a novel farnesyl transferase inhibitor, in patients with solid tumors
25. Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers
26. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety
27. Comparison of potential markers of farnesyltransferase inhibition
28. A peptidomimetic inhibitor of farnesyl:Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
29. Direct demonstration of geranylgeranylation and farnesylation of ki-Ras in vivo
30. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
31. Mouse mammary tumor virus-ki-RasB transgenic mice develop mammary carcinomas that can be growth inhibited by a farnesyl:Protein transferase inhibitor
32. Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells
33. Genomic analysis of metastasis reveals an essential role for RhoC
34. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
35. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyl transferase inhibitors
36. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
37. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice
38. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors
39. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F, and alter the association of CENP-E with the microtubules
40. Going mobile: Microtubule motors and chromosome segregation
41. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
42. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment
43. Farnesyltransferase inhibitors induce cytochrome c release and caspase-3 activation preferentially in transformed cells
44. Activation of the P13'K-AKT pathway masks the proapoptatic effects of farnesyl transferase inhibitors
45. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines
46. The phospholnositide 3-OH kinase/AKT2 pathway as a critical target for farnesyl-transferase-induced apoptosis
47. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
48. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cispiatin, Taxol, and gemcitabine
49. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1
50. Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction?
51. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
52. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
53. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced downregulation of p27(Kip1)
54. Inhibition of protein geranylgeranylation causes a superinduction of nitric oxide synthase-2 by interleukin-1β in vascular smooth muscle cells
55. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells
56. Inhibition of human smooth muscle cell proliferation by farnesyl pyrophosphate analogues, inhibitors of in vitro protein: Farnesyl transferase
57. HMG CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular weight proteins in neonatal rat muscle cell culture
58. Cellular and molecular mechanisms of action of bisphosphonates
59. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
60. Alendronata mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
61. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase
62. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
63. Mechanism of aminobisphosphonate action: Characterization of alendronate inhibition of the isoprenoid pathway
64. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
65. Prenylation inhibitors in renal disease
66. Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I
67. Use of a prenylation inhibitor as a novel antiviral agent
68. Cloning, heterologous expression, and distinct substrate specificity of protein farnesyl-transferase from Trypanosoma brucei
69. The farnesyltransferase inhibitor manumycin A is a novel trypanocide with a complex mode of action including major effects on mitochondria
70. Expression and characterization of protein geranylgeranyltransferase type I from the pathogenic yeast Candida albicans and identification of yeast selective enzyme inhibitors
71. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity
72. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor
73. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in KiRas-overexpressing transformed adrenocortical cells
74. Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins
75. Protein prenylation: Molecular mechanisms and functional consequences
76. Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum
77. Cloning and characterization of a mammalian prenyl protein-specific protease
78. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
79. Disruption of the mouse rce1 gene results in defective Ras processing and mislocalization of Ras within cells
80. Targeted inactivation of the isoprenylcystaine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells
81. Cysteine chloromethyl and diazomethyl ketone derivatives with potent anti-leukemic activity
82. Selective inhibition of Ras-transformed cell growth by a novel fatty acid-based chloromethyl ketone designed to target Ras endoprotease
83. Novel Ras antagonist blocks human melanoma growth